MedTrace Logo

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

NCT04231084 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2024-08-06

No results posted yet for this study

Summary

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Vasodilator testing (Inhaled Nitric Oxide)

Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

DRUG

Vasodilator testing (Inhaled Epoprostenol)

Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Aaron B Waxman, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2024-08-01
Completion
2024-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04231084 on ClinicalTrials.gov